adenovirus vector-based gene therapy (Regeneron)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameadenovirus vector-based gene therapy (Regeneron)
Drug Alias NameAdExTek (Regeneron)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionTEK receptor tyrosine kinase antagonists
TargetsTEK receptor tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A